NCT05782179View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

December 14, 2023

Study Completion Date

May 23, 2024

Conditions
Group B Streptococcal Infections
Interventions
BIOLOGICAL

GBS-NN/NN2

GBS-NN/NN2 bound to alhydrogel as an adjuvant

BIOLOGICAL

Placebo

Normal Saline 0.9 %

Trial Locations (1)

9000

University Hospital Ghent - Centrum voor Vaccinologie (CEVAC) department, Ghent

Sponsors

Lead Sponsor

Minervax ApS
All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

Minervax ApS

OTHER

NCT05782179 - Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants | Biotech Hunter | Biotech Hunter